Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. WVE
stocks logo

WVE

-
Add to WatchlistAdvanced Chart
$
0.000
0(0.000%)1D
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
11.52M
-41.49%
-0.275
+10.02%
12.99M
-269.21%
-0.274
-41.71%
25.98M
-68.98%
-0.212
-178.53%
Estimates Revision
The market is revising Downward the revenue expectations for Wave Life Sciences Ltd. (WVE) for FY2025, with the revenue forecasts being adjusted by -11.03% over the past three months. During the same period, the stock price has changed by 36.27%.
Revenue Estimates for FY2025
Revise Downward
down Image
-11.03%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+5.96%
In Past 3 Month
Stock Price
Go Up
up Image
+36.27%
In Past 3 Month
11 Analyst Rating
up Image0
Wall Street analysts forecast WVE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for WVE is 18.20 USD with a low forecast of 9.00 USD and a high forecast of 24.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Buy
1 Hold
0 Sell
Strong Buy
up Image0
Current: 8.340
sliders
Low
9.00
Averages
18.20
High
24.00
up Image0
Current: 8.340
sliders
Low
9.00
Averages
18.20
High
24.00
Citi
initiated
$16
2025-07-16
New
Reason
Citi
Price Target
$16
2025-07-16
New
initiated
Reason
Citi initiated coverage of Wave Life Sciences with a Buy rating and $16 price target. Wave is a clinical-staged biotech company developing a pipeline of RNA medicines for rare and common diseases, the analyst tells investors in a research note. The firm sees several near-term data catalysts for Wave with potential for upside.
Raymond James
Outperform
initiated
$14
2025-06-10
Reason
Raymond James
Price Target
$14
2025-06-10
initiated
Outperform
Reason
Raymond James assumed coverage of Wave Life Sciences with an Outperform rating and $14 price target as part of a broader research note on selection Biotech names. Risk/reward skews favorably across the sector, though while companies with high PoS - probability of success - lead assets allow for higher conviction, highly attractive skews on less de-risked assets may deliver the most outsized returns, the analyst tells investors in a research note. For the company, the firm is positive on the risk-reward opportunity ahead of second-half catalysts for its two most important clinical-stage programs - WVE-007 in obesity, which features a novel mechanism with differentiating qualities, and WVE-006 in AATD, with second half updates that will include larger cohorts at repeat and higher doses, Raymond James added.
HC Wainwright & Co.
Andrew Fein
Strong Buy
Reiterates
$22
2025-03-26
Reason
HC Wainwright & Co.
Andrew Fein
Price Target
$22
2025-03-26
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Andrew Fein
Strong Buy
Reiterates
$22
2025-03-05
Reason
HC Wainwright & Co.
Andrew Fein
Price Target
$22
2025-03-05
Reiterates
Strong Buy
Reason
Mizuho
Salim Syed
Buy
Maintains
$19 → $22
2024-11-21
Reason
Mizuho
Salim Syed
Price Target
$19 → $22
2024-11-21
Maintains
Buy
Reason
Mizuho raised the firm's price target on Wave Life Sciences to $22 from $19 and keeps an Outperform rating on the shares. The analyst updated models in the biotechnology group following the Q3 reports. The firm says Wave Life remains a potential secular growth story for 2025.
HC Wainwright & Co.
Andrew Fein
Strong Buy
Reiterates
$22
2024-11-13
Reason
HC Wainwright & Co.
Andrew Fein
Price Target
$22
2024-11-13
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for WAVE Life Sciences Ltd (WVE.O) is -7.55, compared to its 5-year average forward P/E of -4.84. For a more detailed relative valuation and DCF analysis to assess WAVE Life Sciences Ltd 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.84
Current PE
-7.55
Overvalued PE
-1.73
Undervalued PE
-7.96

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.14
Current EV/EBITDA
-5.59
Overvalued EV/EBITDA
1.05
Undervalued EV/EBITDA
-5.33

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
12.26
Current PS
19.68
Overvalued PS
20.35
Undervalued PS
4.18

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

WVE News & Events

Events Timeline

(ET)
2025-05-28
08:11:46
Wave Life Sciences announces appointment of Wright as CMO
select
2025-05-08 (ET)
2025-05-08
07:33:05
Wave Life Sciences reports Q1 EPS (29c), consensus (26c)
select
2025-05-06 (ET)
2025-05-06
13:07:28
Controversial doctor Vinay Prasad named CBER director, STAT reports
select
link
Sign Up For More Events
Sign Up For More Events

News

Preview
2.0
07-10NASDAQ.COM
$WVE stock is up 13% today. Here's what we see in our data.

  • Stock Performance: $WVE stock has increased by 13% today with a trading volume of approximately $12.7 million, while insiders have sold shares without any purchases in the last six months.

  • Analyst Ratings and Institutional Activity: Five firms have issued buy ratings for $WVE, with a median price target of $18.0, and there has been notable activity from institutional investors, with 107 adding shares and 69 reducing their positions recently.

Preview
9.0
06-21Newsfilter
Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007's Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA's Annual Scientific Sessions

  • WVE-007 Presentation: Wave Life Sciences presented preclinical data on WVE-007, a GalNAc-siRNA targeting INHBE mRNA, showing its potential as a novel obesity treatment that promotes weight loss while preserving muscle mass and reducing inflammation in adipose tissue.

  • Clinical Implications: The findings suggest that WVE-007 could transform obesity treatment by providing effective fat loss with infrequent dosing, and it is currently being evaluated in the ongoing INLIGHT clinical trial, with initial clinical data expected later this year.

Preview
5.0
06-14NASDAQ.COM
Insider Sale: Director at $WVE Sells 30,000 Shares

  • Insider Trading Activity: Gregory L. Verdine, a director at $WVE, sold 30,000 shares for approximately $208,500, representing about 9.6% of his holdings, leaving him with 282,517 shares. In the past six months, there have been three insider sales and no purchases of $WVE stock.

  • Institutional Investor Movements: In the latest quarter, 113 institutional investors increased their positions in $WVE, while 89 reduced theirs, indicating mixed sentiment among institutional stakeholders regarding the company's stock.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is WAVE Life Sciences Ltd (WVE) stock price today?

The current price of WVE is 8.34 USD — it has increased 4.12 % in the last trading day.

arrow icon

What is WAVE Life Sciences Ltd (WVE)'s business?

Wave Life Sciences Ltd. is a biotechnology company. The Company is focused on unlocking the potential of RNA medicines (oligonucleotides), or those targeting ribonucleic acid (RNA), to transform human health. Its RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing and RNA interference (RNAi), providing Company with capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a preclinical program in obesity. These programs include WVE-N531, WVE-006 and WVE-003. It is also building a pipeline of novel A-to-I RNA editing oligonucleotides (AIMers).

arrow icon

What is the price predicton of WVE Stock?

Wall Street analysts forecast WVE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for WVE is 18.20 USD with a low forecast of 9.00 USD and a high forecast of 24.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is WAVE Life Sciences Ltd (WVE)'s revenue for the last quarter?

WAVE Life Sciences Ltd revenue for the last quarter amounts to 9.18M USD, decreased -26.82 % YoY.

arrow icon

What is WAVE Life Sciences Ltd (WVE)'s earnings per share (EPS) for the last quarter?

WAVE Life Sciences Ltd. EPS for the last quarter amounts to -0.29 USD, increased 20.83 % YoY.

arrow icon

What changes have occurred in the market's expectations for WAVE Life Sciences Ltd (WVE)'s fundamentals?

The market is revising Downward the revenue expectations for Wave Life Sciences Ltd. (WVE) for FY2025, with the revenue forecasts being adjusted by -11.03% over the past three months. During the same period, the stock price has changed by 36.27%.
arrow icon

How many employees does WAVE Life Sciences Ltd (WVE). have?

WAVE Life Sciences Ltd (WVE) has 287 emplpoyees as of July 19 2025.

arrow icon

What is WAVE Life Sciences Ltd (WVE) market cap?

Today WVE has the market capitalization of 1.30B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free